Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $182.00 at Morgan Stanley

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective cut by research analysts at Morgan Stanley from $196.00 to $182.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price objective points to a potential upside of 267.74% from the stock’s current price.

SRPT has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada cut shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Scotiabank lowered their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Deutsche Bank Aktiengesellschaft lowered their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Finally, Wells Fargo & Company began coverage on Sarepta Therapeutics in a research report on Friday. They set an “overweight” rating and a $115.00 target price on the stock. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $161.83.

Sarepta Therapeutics Stock Down 1.6 %

Shares of SRPT traded down $0.82 during midday trading on Friday, hitting $49.49. The company had a trading volume of 903,770 shares, compared to its average volume of 1,371,806. Sarepta Therapeutics has a 1 year low of $48.01 and a 1 year high of $173.25. The firm has a market capitalization of $4.80 billion, a P/E ratio of 39.52 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company’s 50-day simple moving average is $89.37 and its 200-day simple moving average is $110.71.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.